Accendra Health (ACH) risk factors, FY2024 10-K

Risks Related to Our Debt

1. 01Forward-Looking Statements and Risk Factors Summary
2. 38We may not be able to generate sufficient cash to service our debt and other obligations
3. 39be able to consummate those dispositions or to obtain the proceeds that we could realize from them, and these proceeds may not be adequate to meet any debt service obligations then due
4. 40We may not be able to refinance, extend or repay our substantial indebtedness which would have a material adverse effect on our financial condition
5. 41Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility
6. 42Our variable rate indebtedness subjects us to interest rate risk, which could cause our indebtedness service obligations to increase significantly
7. 43Despite current indebtedness levels, we will incur substantially more debt to complete the Rotech Acquisition
8. 44Despite current indebtedness levels, we may continue to incur indebtedness in the future, and the amount of that additional indebtedness may be substantial, which could further exacerbate the risks described herein
9. 45Our continued success is substantially dependent on positive perceptions of our reputation
10. 46We are subject to risks related to public health crises, future outbreaks of health crises or other adverse public health developments
11. 47Further, actions by the U.S. government or other foreign governments in response to any such public health developments could adversely affect our business and operations, such as closure of one or more facilities for an unknown period of time
12. 48The market price for our common stock and debt have been, and may continue to be, highly volatile
13. 49Our global operations increase the extent of our exposure to the economic, political, currency, regulatory and other risks of international operations
14. 50We may be adversely affected by global climate change or by legal, regulatory or market responses to such change

Industry and Economic Risks

1. 02Litigation & Regulatory Risks
2. 19We face increasing competition, accelerating pricing pressure and changes in technology
3. 20An inability to obtain key components, raw materials or manufactured products from third parties in a timely and cost-effective manner, or a material disruption in our supply chain, may have a material adverse effect on our business
4. 21Uncertainty about current and future economic conditions and other adverse changes in general political conditions may adversely affect demand for our products and services and collectability of our accounts receivable
5. 22consequences of financial and economic decline could have a material adverse effect on our business, results of operations, financial condition and cash flows
6. 23Our Products & Healthcare Services segment is exposed to price fluctuations of key commodities, which may negatively impact our results of operations and cash flows
7. 24Changing conditions in the U.S. healthcare industry may impact our results of operations and cash flows
8. 25Our profitability and cash flows may vary based on the impacts of rising inflationary pressures
9. 26We are subject to stringent regulatory and licensing requirements, and we have been, are and could become the subject of federal and state investigations and compliance reviews
10. 27We must obtain clearance or approval from appropriate regulatory authorities prior to consummating transactions of certain healthcare related businesses
11. 28Our failure to comply with regulatory requirements or receive regulatory clearances or approvals for our medical gas facilities, products or operations could adversely affect our business
12. 29Our business may be adversely affected if we are unable to adequately establish, maintain, protect and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of such rights
13. 30We may become subject to litigation, investigations, claims and other legal proceedings brought by regulatory agencies, third parties, or individuals
14. 31We may incur product liability losses, litigation liability, product recalls, safety alerts or regulatory action associated with the provision of healthcare services, and the products that we source, assemble, manufacture and sell which can be costly and disruptive to our business
15. 32there is no guarantee that future recommendations or sanctions will be resolved on the same timeline or favorably, if at all
16. 33We could be subject to adverse changes in the tax laws or challenges to our tax positions
17. 34Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities
18. 35Our aspirations, goals and disclosures related to ESG matters expose us to numerous risks, including risks to our reputation and stock price
19. 36including media campaigns and litigation, to advance their perspectives. To the extent we are subject to such activism, it may require us to incur costs or otherwise adversely impact our business
20. 37Our amended and restated bylaws designates the U.S. District Court for the Eastern District of Virginia as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us

Operational Risks

1. 03We have concentration in and dependence on certain healthcare provider customers, Group Purchasing Organizations, and Payors
2. 04Our failure to establish and maintain relationships with hospital and physician referral sources may cause our revenue to decline
3. 05Possible changes in customer and product mix could have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity
4. 06Our business is dependent on certain significant suppliers
5. 07Our operations depend on the proper functioning of information systems, and our business or results of operations could be adversely affected if we experience a cyberattack or other systems breach or failure
6. 08An interruption in the ability of our business to manufacture products or the proper functioning of critical facilities and distribution networks may have a material adverse effect on our business and operations
7. 09Our capitation arrangements may prove unprofitable if actual utilization rates exceed our assumptions
8. 10Our ability to attract and retain talented and qualified teammates is critical to our success and competitiveness
9. 11We cannot assure you that the potential sale of the Products & Healthcare Services segment will be completed; and there may be negative impacts on our business, financial results, and operations
10. 12We cannot assure you that the proposed acquisition of Rotech (Rotech Acquisition) will be completed
11. 13We may fail to realize the anticipated benefits of the Rotech Acquisition or those benefits may take longer to realize than expected. We may also encounter significant difficulties in integrating the Rotech business into our operations
12. 14We and the Rotech business will be subject to business uncertainties while the Rotech Acquisition is pending that could adversely affect our business and the Rotech business
13. 15The pendency of the Rotech Acquisition could adversely affect our business, financial results, and operations
14. 16Our inability to adequately integrate acquisitions could have a material adverse effect on our operations
15. 17Our operations involve the storage, transportation and provision of compressed and liquid oxygen, which carries an inherent risk of rupture or other accidents with the potential to cause substantial loss
16. 18Our goodwill may become further impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles